Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID‐19 Clinical Trials

• Váldodahkkit: Jim H. Hughes (Dahkki), Kevin Sweeney (Dahkki), Sima Ahadieh (Dahkki), Daniele Ouellet (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2020-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Azithromycin (AZ), a broad‐spectrum macrolide antibiotic, is being investigated in patients with coronavirus disease 2019 (COVID‐19). A population pharmacokinetic model was implemented to predict lung, intracellular poly/mononuclear cell (peripheral blood monocyte (PBM)/polymorphonuclear leukocyte (...